198 related articles for article (PubMed ID: 27756654)
1. Interstitial lung disease caused by oxaliplatin. An uncommon but not unknown complication.
Sánchez Cendra C; Juez Martel I; Gutierrez Abad D
Arch Bronconeumol; 2017 Apr; 53(4):213-215. PubMed ID: 27756654
[No Abstract] [Full Text] [Related]
2. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer.
Gagnadoux F; Roiron C; Carrie E; Monnier-Cholley L; Lebeau B
Am J Clin Oncol; 2002 Aug; 25(4):388-90. PubMed ID: 12151971
[TBL] [Abstract][Full Text] [Related]
3. [Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin].
Park S; Jung JJ; Kim GB; Yoon HS; Ko SH; Ko JE; Lee YS
Korean J Gastroenterol; 2010 May; 55(5):340-3. PubMed ID: 20697195
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
[No Abstract] [Full Text] [Related]
5. Interstitial lung disease associated with oxaliplatin: description of two cases.
Pena Alvarez C; Suh Oh HJ; Sáenz de Miera Rodríguez A; García Arroyo FR; Covela Rúa M; Salgado Boquete L; López Clemente PM; Constenla Figueiras M
Clin Transl Oncol; 2009 May; 11(5):332-3. PubMed ID: 19451069
[No Abstract] [Full Text] [Related]
6. Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report.
Mitsuboshi S; Kozakai H; Yamada H; Nagai K; Furukawa T; Aizawa K
J Oncol Pharm Pract; 2018 Oct; 24(7):540-543. PubMed ID: 28696176
[TBL] [Abstract][Full Text] [Related]
7. [Incidence and management of adverse events in FOLFOX plus bevacizumab therapy for colorectal cancer].
Shimodaira H
Nihon Rinsho; 2015 Feb; 73 Suppl 2():582-6. PubMed ID: 25831827
[No Abstract] [Full Text] [Related]
8. Organizing pneumonia with fatal outcome after adjuvant chemotherapy with FOLFOX.
Vargas A; Montironi C; Buxó E
Arch Bronconeumol; 2015 Nov; 51(11):610. PubMed ID: 26163115
[No Abstract] [Full Text] [Related]
9. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W
Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039
[No Abstract] [Full Text] [Related]
10. Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
Usui K; Katou Y; Furushima K; Tanaka Y; Tanai C; Ishihara T
Jpn J Clin Oncol; 2011 Apr; 41(4):498-502. PubMed ID: 21303791
[TBL] [Abstract][Full Text] [Related]
11. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
[No Abstract] [Full Text] [Related]
12. Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy.
Lai JI; Wang WS; Lai YC; Lin PC; Chang SC
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):425-8. PubMed ID: 20557834
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
[TBL] [Abstract][Full Text] [Related]
14. [Standard chemotherapy for colonic neoplasms].
Hyodo I
Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):283-8. PubMed ID: 17370594
[No Abstract] [Full Text] [Related]
15. Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm.
Vargo CA; Blazer M; Reardon J; Gulati M; Bekaii-Saab T
Clin Colorectal Cancer; 2016 Jun; 15(2):e61-3. PubMed ID: 26701613
[No Abstract] [Full Text] [Related]
16. Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule.
Schüll B; Kornek GV; Scheithauer W
Ann Oncol; 2001 Nov; 12(11):1653-4. PubMed ID: 11822769
[No Abstract] [Full Text] [Related]
17. [Ambulatory chemotherapy schedule for metastatic colorectal cancer].
Watine J; Soulage C
Presse Med; 2001 Jan; 30(1):35. PubMed ID: 11210587
[No Abstract] [Full Text] [Related]
18. Fatal pneumonitis induced by oxaliplatin.
Arévalo Lobera S; Sagastibeltza Mariñelarena N; Elejoste Echeberría I; Melé Olivé M; Egaña Otaño L; Basterretxea Badiola L; La Casta Muñoa A; Azkue Gabilondo M
Clin Transl Oncol; 2008 Nov; 10(11):764-7. PubMed ID: 19015075
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
Cobo F; De Celis G; Pereira A; Latorre X; Pujadas J; Albiol S
Anticancer Drugs; 2007 Sep; 18(8):973-6. PubMed ID: 17667605
[TBL] [Abstract][Full Text] [Related]
20. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
